Formula Growth Ltd. Makes New $1.83 Million Investment in Insulet Corporation $PODD

Posted by Francis Steltz on Aug 28th, 2026

Formula Growth Ltd. purchased a new stake in Insulet Corporation (NASDAQ:PODD – Free Report) during the 2nd quarter, Holdings Channel reports. The fund purchased 11,991 shares of the medical instruments supplier’s stock, valued at approximately $1,826,000.

Several other large investors have also modified their holdings of PODD. Jefferies Financial Group Inc. purchased a new position in shares of Insulet during the 2nd quarter worth approximately $7,371,000. Public Employees Retirement System of Ohio purchased a new stake in Insulet in the 2nd quarter valued at approximately $3,023,000. Capstone Investment Advisors LLC purchased a new stake in Insulet in the 2nd quarter valued at approximately $599,000. Proficio Capital Partners LLC acquired a new stake in Insulet during the 2nd quarter valued at $535,000. Finally, Corient Private Wealth LP acquired a new stake in Insulet during the 2nd quarter valued at $13,686,000.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the purchase, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.36% of the company’s stock.

More Insulet News

Here are the key news stories impacting Insulet this week:

Positive Sentiment: Wall Street’s outlook remains a potential support for Insulet, with the latest analyst discussion examining whether the company’s long-term growth prospects and Omnipod franchise can outweigh recent execution concerns. Is Wall Street bullish or bearish on Insulet stock?
Neutral Sentiment: Insulet said it will participate in the Wells Fargo 21st Annual Healthcare Conference, giving investors an opportunity to hear directly from management about demand, manufacturing, product quality and financial guidance. The event could become a catalyst if management provides reassuring updates, but no new information was disclosed in the announcement. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
Neutral Sentiment: A former Insulet global customer-experience executive, Curtis Kopf, was appointed to a similar leadership role at Kestra Medical Technologies. The move is not a financial update for Insulet, although investors may monitor whether it affects customer-support or digital-transformation initiatives. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
Negative Sentiment: Several firms, including Rosen, Bronstein Gewirtz & Grossman, SBS, DJS and others, are seeking investors to serve as lead plaintiff in a securities-fraud lawsuit against Insulet and certain officers. The complaints allege that the company made misleading statements or failed to disclose manufacturing and quality-control problems, including risks associated with Omnipod corrections. The allegations have not been proven, but the litigation creates potential legal costs, reputational damage and regulatory uncertainty. Rosen Insulet securities class-action notice

Insulet Stock Up 0.0%

PODD stock opened at $143.41 on Friday. The company has a 50 day moving average price of $154.47 and a two-hundred day moving average price of $181.40. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The stock has a market capitalization of $9.95 billion, a P/E ratio of 26.81, a PEG ratio of 1.13 and a beta of 1.10. Insulet Corporation has a one year low of $126.40 and a one year high of $354.88.

Insulet (NASDAQ:PODD – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.19. The business had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The business’s revenue was up 23.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, sell-side analysts expect that Insulet Corporation will post 6.51 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on PODD shares. Raymond James Financial reissued an “outperform” rating and set a $180.00 price target on shares of Insulet in a research report on Thursday, August 6th. Robert W. Baird set a $175.00 price objective on Insulet in a research report on Thursday, August 6th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $152.00 price objective (down from $275.00) on shares of Insulet in a research note on Thursday, August 6th. Wells Fargo & Company cut Insulet from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $255.00 to $144.00 in a research report on Wednesday, August 5th. Finally, William Blair started coverage on shares of Insulet in a research note on Wednesday, May 20th. They issued an “outperform” rating for the company. Fourteen investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $195.40.

Read Our Latest Research Report on Insulet

Insulet Profile

(Free Report)

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.